Marie-Pier Fontaine

Encadrement de l'intelligence artificielle touchant les arts et la culture Défense de l'exception culturelle dans les accords de libre-échange, incluant dans les dispositions sur le commerce numérique et l'intelligence artificielle Revendications pour conserver la réglementation canadienne en radiodiffusion Possiblement démontrer l'importance économique de notre industrie et l'importance de maintenir Téléfilm Canada, la Société Radio-Canada/Canadian Broadcasting Corporation et le Fonds canadien de télévision Loi sur les télécommunications - aspects sur la propriété canadienne, le champ d'application de la loi, les pouvoirs du CRTC et la politique canadienne des télécommunications Loi sur le droit d'auteur. L'aspect de la loi relatif à l'audiovisuel. Loi sur la radiodiffusion- disposition sur le mandat de Radio-Canada, sur les pouvoirs du CRTC et sur la politique canadienne de la radiodiffusion Défense pour le maintien de toutes les aides gouvernementales dans notre industrie. Programmes offerts par Téléfilm Canada et le Fonds Canadiens de Télévision, en production et développement. Défense de la production indépendante

Bill C-64 (Pharmacare Act - 2024) Patented Medicine Prices Review Board (PMPRB) Reform Most Favored Nation National Pharmacare Drugs for Rare Diseases

Seeking to ensure the interests of Canada’s independent producers are considered in any artificial intelligence (AI) policies or regulations, including the National AI Strategy. Seeking to ensure the interests of Canada’s independent producers are considered in any amendments to the Broadcasting Act, Telecommunications Act, Online Streaming Act or Copyright Act. Seeking to ensure that producers are able to receive labour market opinions in a timely manner Seeking to ensure that appropriate Temporary Foreign Workers (TFWs) in the film and television industry are exempt from the 4-year cap on working in Canada as provided in the Regulations Amending the Immigration and Refugee Protection Regulations. Seeking the creation of new private investment incentives through modifications to the Income Tax Act or other appropriate legislation Seeking CRTC-mandated contributions by internet service providers, wireless service providers, and online broadcasters to the creation and presentation of Canadian programming from the independent production sector Request funding for the creation of a mentorship program aimed at developing skill sets and acquiring work experience in the film, television and interactive media industry. Participation in Creative Export Canada via the Minister of Small Business and Export Promotion Participating in guideline consultations for all programs administered by Telefilm Canada Funding from Canadian Heritage for the production of annual research report "Profile: An Economic Report on the Canadian Film and Television Industry" Department of Canadian Heritage co-production policy with regard to international production treaties CRTC Canadian program certification relating to criteria used to determine Canadian content of productions Canadian Audio-Visual Certification - relating to criteria for obtaining CAVCO certification of a production Canada Income Tax Act relating to Canadian Film or Video Production Tax Credit program and to Film or Video Production Services Tax Credit Program Broadcasting regulations, including regulations related to Canadian programming. Broadcasting polices, including policies related to Canadian programming expenditures, digital media, and independently-produced programming.

Federal role in the health system as it relates to funding, the use of federal spending power, and pan-Canadian priorities, including in the areas of physical and digital infrastructure, health workforce, immigration, aging, older adult care, child and youth health, mental health and substance use, palliative care, cybersecurity, Indigenous health, environment, and data. Advancing Canada’s health research and innovation agenda as it relates to funding, policy and program design, and regulatory matters, including in the areas of clinical trials and development of innovative medical treatments.

Policy measures to ensure security of drug supply in Canada and preserve Canada’s attractiveness for biopharmaceutical launches, including in response to foreign pricing regulations. Policies and frameworks to accelerate access to innovative medicines post-Health Canada approval, including efforts to reduce time to reimbursement and streamline federal/provincial listing processes. Discussion focused on sharing perspectives on priorities and resourcing. In particular, a shared observation of an increase in submission reviews exceeding established timeframes and increasing challenges with securing pre-filing meetings were discussed Agreement on Trade-Related Aspects of Intellectual Property Rights (TRIPs) with respect to the protection of data, Access to Medicines, and TRIPs "flexibility". Merck is seeking to ensure Canada's continued compliance with its obligations under TRIPs relevant to the biopharmaceutical industry within all domestic legislation in addition to ongoing and future trade negotiations. Relevant domestic legislation includes the Food and Drugs Act, the Patent Act, and related regulations and guidance documents. Beyond TRIPs, Merck is seeking enhancements to increase the stability and global competitiveness of Canada’s intellectual Property legislation, regulations and policies relevant to the biopharmaceutical industry. Such enhancements may result from domestic policy in addition to bilateral and multilateral trade negotiations (e.g. Comprehensive Economic and Trade Agreement (CETA) and the Trans-Pacific Partnership (TPP). World Health Organization issues concerning pharmaceuticals as it relates to Counterfeits, Access to Medicines, and the Intergovernment Working Group (IGWG). US - Canada Regulatory Cooperation Council (RCC) as it relates to the regulation of biopharmaceutical products. The government's Science and Technology strategy as it relates to the biopharmaceutical industry. Subsequent Entry Biologics (SEBs) as it relates to Regulations, Policies, or Guidelines being developed by Health Canada, specifically the Draft Guidance Document on SEBs, the Notices of Changes to Health Canada's Guidance Documents on Data Protection and Patented Medicines Regulations (Notice of Compliance) Regulations. Smart Regulations as it relates to the biopharmaceutical industry. Scientific Research and Educational Design (SR&ED) Tax Credit in respect of updating the system and increasing the expenditure limit for refundable credits. Policies and programs as it relates to vaccine approval, procurement and public awareness of immunization. Plan design and reimbursement policies for drug plans administered by Federal Government including NIHB and Corrections Services. Pharmaceutical pricing policy issues arising from the jurisdiction of the Patended Medicines Prices Review Board (PMPRB) and R&D reporting. Patented Medicines Regulations as it relates to the regulation and protection of biopharmaceutical products. Patented Medicines (Notice of Compliance) Regulations with respect to ensuring that patent rights are respected and are internationally competitive. Patented Medicines (Notice of Compliance) Regulations as it relates to the regulation of intellectual property for biopharmaceutical products. Patent Act as it relates to reporting requirements and pricing guidelines, and the protection of intellectual property in biopharmaceutical products. Partnership opportunities as it relates to Canada's policy and programs to improve health in the developing world, such as Maternal and Child Health. New Substances Notification Regulations as it relates to the biopharmaceutical industry. National Pharmaceutical Strategy as it relates to the federal government's involvement in federal/provincial access to medicines framework. Income Tax Act as it relates to biopharmaceutical products. Health Canada's Legislative and Regulatory Modernization (LRM) as it relates to the review, approval, transparency and compliance activities of biopharm

Free trade agreements as they relate to the biopharmaceutical industry. Biomanufacturing and Life Sciences Strategy (BLSS) as it relates to the biopharmaceutical industry. Policies and frameworks to accelerate access to innovative medicines post-Health Canada approval, including efforts to reduce time-to-reimbursement and streamline federal/provincial listing processes. Bill C-64, the Pharmacare Act, with respect to definitional questions related to terms contained in Section 6.1, and concerns regarding the increased risk of drug shortages. Communication around existing drug shortages and shared solutions to mitigate the impact on Canadians. Advocate for the implementation of a federal diabetes and obesity strategy. Advocate for the establishment of public-private partnerships to support chronic disease prevention.